Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of S-588410 in advanced or metastatic bladder cancer controlled after first-line chemotherapy
2013-005274-22Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2014
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of S-588410 in bladder cancer and transitional cell carcinoma (TCC), sponsored by Shionogi & Co., Ltd. Primary endpoint: CTL induction rate within 12 weeks after initial dose. Started May 2014; status: completed.
02
Drugs
S-588410
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2013-005274-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005274-22.